INTRODUCTION
The number of cardiac implantable electronic devices (CIEDs) implanted worldwide continues to increase with a corresponding increased need for CIED extraction which carries significant acute morbidity and mortality. [1] [2] [3] Transvenous lead extraction (TLE) may be necessary due to CIED infection, which may present as localized infection/erosion or systemic infection. 4, 5 Systemic infection is an independent predictor of 30-day mortality; however, the outcomes of patients undergoing TLE with localized compared to systemic infection is less clear. We set out to evaluate the differences of 30-day all-cause mortality between infective and noninfective groups as well as predictors of 30-day mortality for both infective and systemic infection cohorts. We hypothesized that patients with systemic infection indication for TLE would have a higher procedure-related major complication and 30-day mortality rate compared to patients with localized pocket infection/erosion. To assess this, we specifically compared the differences between patients with systemic and local infection undergoing TLE.
Consecutive patients undergoing TLE at a high-volume lead extraction center between October 2000 and December 2016 were prospectively recorded onto a computer database. Multiple parameters including patient demographics, comorbidities, device and lead type, indication for extraction, procedural success, major complications, and 30-day mortality were incorporated into the database. The database collection and analysis were approved by the Institutional Review Board of Guy's and St Thomas' Hospital. For the current analysis, the type of TLE was dichotomized into "Infective" and "Noninfective"
indications. The infective indication group was further dichotomized into systemic infection and local infection indication subgroups to assess differences in procedural outcomes and clinical characteristics.
We analyzed predictors of 30-day mortality for the infective group and also for the systemic infection subgroup, both of which are thought to be higher risk groups. The clinical notes were reviewed to determine the clinical pathway of all patients undergoing TLE who died within 30 days following their extraction procedure.
Extraction procedure
TLEs were performed by experienced operators in a cardiac catheter laboratory, hybrid cardiac theatre, or cardiac theatre with immediate onsite cardiothoracic surgical cover. The majority of procedures were undertaken in the cardiac catheterization laboratory with formal surgical cover. Patients deemed to be higher risk due to factors such as prolonged lead dwell time underwent TLE in a dedicated cardiac hybrid theater or cardiac theater with mobile fluoroscopic screening equipment. The preferred initial route was a superior approach where possible with a subsequent stepwise approach undertaken. Initially, manual traction with the aid of a locking stylet (e.g., Liberator Universal Locking Stylet, Cook Medical, Leechburg, PA, USA or LLD R Lead locking device, Spectranetics, Colorado Springs, CO, USA) was performed.
An Excimer laser (e.g., Model CVX-300, Spectranetics) was adopted if a lead was not extractable with manual traction. Other techniques including mechanical tools (e.g., Tightrail Rotating dilator sheath)
were used if laser extraction was unsuccessful, followed by a femoral approach employing snares. All patients underwent transthoracic echocardiography post-TLE (unless intraoperative transesophageal echocardiography was used) to assess for a hemodynamically significant pericardial effusion and valve damage as well as a chest radiograph.
Definitions
Renal impairment was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/ 
RESULTS
A total of 925 percutaneous TLEs were performed by five different first operators between October 2000 and December 2016.
Note that 505 TLE procedures were performed for infection (infective group) and 420 for noninfective indication (noninfective group).
The infective group was further dichotomized into systemic infection (n = 164) and local infection (n = 341) to assess predictors of 30-day mortality.
Infective versus noninfective groups
Demographics for infective and noninfective groups are shown in Table 1 . Patients with an infective indication were significantly older than the noninfective group (68 ± 14 years vs 62 ± 15 years, P < 0.001) and more likely male (78% vs 67%, P < 0.001). The infective group had a higher mean left ventricular ejection fraction (LVEF) at extraction (46% ± 14% vs 42% ± 15%, P = 0.003) and significantly fewer patients with severe left ventricular systolic dysfunction (LVSD, defined as LVEF ≤ 35%) (27.8% vs 39.0%, P = 0.004). Infective patients had a significantly higher prevalence of renal impairment (21.2% vs 15.9%, P = 0.048) but a lower incidence of chronic obstructive pulmonary disease (9.0% vs 13.8%, P = 0.024). Multiplicity of comorbidities was balanced for both groups. Table 2 demonstrates clinical features and procedural characteristics for infective and noninfective groups. The mean dwell time of extracted leads were similar between the infective and noninfective groups (7.3 ± 6.8 years vs 6.8 ± 6.8 years, P = NS). The mean number of leads extracted was significantly higher in the infective group (2.2 ± 1.0 leads vs 1.8 ± 0.9 leads, P < 0.001). The vast majority of cases were initially performed from the superior approach (97.8%). Femoral extraction was required in 5.3% (n = 48) of cases with no difference for infective and noninfective groups in this respect.
Laser extraction was employed in 56% of cases (56.0% in the infective and 56.1% in the noninfective group, P = NS). Overall, clinical failure occurred in 13 patients (1.4%) and was not significantly different between the infective and noninfective groups (1.6% vs 1.2%, P = NS).
Positive microbiology was more prevalent in the infective indication group (64.2% vs 6.4%, P < 0.001). Table 2 shows procedural outcomes for infective versus noninfective groups. The 30-day procedure-related major complication rate including procedure-related deaths was 1.4% (13 cases) and was comparable between the infective and noninfective groups (1.8%, n = 9 vs 1.0%, n = 4, P = 0.402). This was also similar between the two groups when divided into intraprocedural (1.8%, n = 9 vs 0.7%, n = 3, P = 0.243) and postprocedural (0% vs 0.2%, n = 1, P = 0.454) major complications including deaths. The procedure-related mortality rate was 0.3% (n = 3) and was similar between the infective and noninfective groups (0.6%, n = 3 vs 0%, P = 0.256). This was again consistent between the two groups when divided into intraprocedural (0.2%, n = 1 vs 0%, P = NS) and postprocedural (0.4%, n = 2 vs 0%, P = NS) deaths.
Complications and mortality for infective versus noninfective groups
The emergency thoracotomy rate was similar between the two groups (1.2%, n = 6 vs 0.2%, n = 1, P = 0.135) with an overall emergency thoracotomy rate of 0.8%. The all-cause 30-day major complication rate including all deaths was significantly higher in the infective group (5.1%, n = 26 vs 1.2%, n = 5, P = 0.001). In addition, the all-cause 30-day mortality rate was significantly higher in the infective indication group (4.0%, n = 20 vs 0.2%, n = 1, P < 0.001). Furthermore, the 30-day nonprocedure-related mortality rate was significantly higher in the infective cohort (3.4%, n = 17 vs 0.2%, n = 1, P < 0.001). Table 3 demonstrates that the majority of all-cause mortality occurred in the infection indication group and was due to sepsis. There was only one death in the noninfective cohort which was attributed to end-stage heart failure.
Systemic versus local infection
Device, lead, and patient characteristics for systemic and local infection subgroups are included in Table 4 . Both subgroups (systemic vs local infection) were balanced for age (68 ± 14 years vs 68 ± 14 years, P = 0.697), gender (79% vs 77%, P = 0.731), and mean LVEF at time of the extraction (46% ± 14% vs 46% ± 14%, P = 0.716). Both groups had similar numbers of patients with renal impairment (22.8% vs 20.5%, P = 0.556). There were significantly greater number of patients with previous valve repair or replacement in the systemic infection group (17.0% vs 9.3%, P = 0.022). Multiplicity of comorbidities was balanced for both groups. Table 5 demonstrates clinical features and procedural characteristics for systemic and local infection subgroups. The mean lead dwell time was similar between subgroups (6.8 ± 6.8 years vs 7.5 ± 6.7 years, P = 0.106) as was the mean number of leads extracted per case (2.2 ± 1.0 vs 2.2 ± 1.0, P = 0.547). Positive microbiology was more prevalent in the systemic infection subgroup (89.7% vs 52.2%, P < 0.001), as was presence of lead or valve vegetation prior to TLE (36.7% vs 0%, P < 0.001). There was no significant difference between systemic and local subgroups for superior and inferior approaches to TLE. Clinical failure rates were comparable between subgroups (2.5% vs 1.2%, P = 0.283). Abbreviations: CABG = coronary artery bypass graft; COPD = chronic obstructive pulmonary disease; CRT = cardiac resynchronization therapy; CRT-P = cardiac resynchronization therapy pacemaker; CRT-D = cardiac resynchronization therapy cardioverter-defibrillator; CS = coronary sinus; ICD = implantable cardioverter-defibrillator; IHD = ischemic heart disease; LV = left ventricular; LVEF = left ventricular ejection fraction; LVSD = left ventricular systolic dysfunction; PVD = peripheral vascular disease; RA = right atrial; RV = right ventricular; SD = standard deviation; TLE = transvenous lead extraction. a Lead numbers are represented as binary data for the purposes of this analysis Table 1 .
Clinical features and procedural characteristics for systemic versus local infection

Complications and mortality for systemic versus local infection
including procedure-related deaths was similar between the systemic and local infection indication subgroups (2.4%, n = 4 vs 1.5%, n = 5, P = 0.481). The procedure-related mortality rate was similar between the two subgroups (1.2%, n = 2 vs 0.3%, n = 1, P = 0.247). This was consistent between the two subgroups when divided into intraprocedural (0.6%, n = 1 vs 0%, P = NS) and postprocedural (0.6%, n = 1 vs 0.3%, n = 1, P = NS) deaths. The emergency thoracotomy rate was similar between the two subgroups (1.2%, n = 2 vs 1.2%, n = 4, P = NS).
The all-cause 30-day major complication rate including all deaths was significantly higher in the systemic infection subgroup (9.1%, n = 15 vs 3.2%, n = 11, P = 0.008). In addition, the all-cause 30-day mortality rate was significantly higher in the systemic infection subgroup (7.9%, n = 13, vs 2.1%, n = 7, P = 0.003). Furthermore, the 30-day nonprocedure-related mortality rate was significantly higher in the systemic infection subgroup (6.7%, n = 11 vs 1.8%, n = 6, P = 0.007). Table 6 shows that the majority of deaths was due to sepsis and occurred in the systemic infection indication subgroup. Myocardial infarction 0% (n = 0/505) 0% (n = 0/420) 0% (n = 0/925) Abbreviations: CRP = C-reactive protein; IQR = interquartile range; SD = standard deviation; SVC = superior vena cava; TLE = transvenous lead extraction. † If more than one major complication (including death) occurred for a single TLE procedure, only one major complication or death was counted when calculating the "procedure-related major complication including procedure-related death" rate. ‡ The nonprocedure-related respiratory arrest in the noninfective group was secondary to pneumonia. Abbreviations: SVC = superior vena cava. † 30-day procedure-and nonprocedure-related causes of death.
TA B L E 2 Clinical characteristics and procedural outcomes for infective and noninfective groups
TA B L E 3 Breakdown of causes of 30-day mortality for infective and noninfective groups
Causes of 30-day mortality
Predictors of 30-day all-cause mortality in the infective indication group
In the infective indication group, univariate analysis showed age, renal impairment, prior valve surgery, elevated pre-TLE C-reactive protein (CRP), and systemic infection were associated with 30-day all-cause mortality ( Figure 1A ). Renal impairment, systemic infection, and elevated preprocedure CRP were independent predictors of 30-day allcause mortality in patients undergoing TLE for an infective indication ( Figures 1B and C) .
Predictors of 30-day all-cause mortality in the systemic infection subgroup
In the systemic infection subgroup, univariate analysis showed that only renal impairment and elevated preprocedure CRP were associated with all-cause 30-day mortality (Figure 2 ). There were no deaths in patients with diabetes mellitus in the systemic infection subgroup.
No independent predictors of 30-day mortality were identified in the systemic infection subgroup at multivariate analysis.
DISCUSSION
To our knowledge, we report the first analysis detailing predictors of 30-day mortality in patients undergoing TLE with an infective indication as well as comparing outcomes between systemic infection and local infection subgroups. Overall, the infective cohort had a significantly greater number of patients with renal impairment compared to patients with a noninfective indication for TLE (21.2% vs 15.9%, P = 0.048); however, there was no statistical difference between the two groups for multiplicity of comorbidities.
In fact, there were a significantly greater number of patients with severe LVSD with an LVEF ≤35% in the noninfective group compared to the infective group (39.0% vs 27.8%, P = 0.004). As expected, there were significantly more patients with positive microbiology in the infective group (64.2% vs 6.4%, P < 0.001). The small number of patients with positive microbiology in the noninfective group were due to organisms not typically responsible for CIED infection and related to distant organ infection, for example, urinary tract infection.
TA B L E 4 Cardiac implantable electronic device, lead, and patient characteristics for local versus systemic infection subgroups
Systemic infection Local infection
Device type (n = 164) (n = 341) P-value 
Systemic versus local infection
When comparing systemic with local infection, there was a signif- 
TA B L E 5 Clinical characteristics and procedural outcomes for systemic and local infection subgroups
Systemic infection Local infection
Clinical features for TLE (n = 164) (n = 341) P-value 
All-cause 30-day major complications including deaths
All-cause 30-day major complication including deaths † 9.1% (n = 15/164) 3.2% (n = 11/341) 0.008
All-cause 30-day mortality 7.9% (n = 13/164) 2.1% (n = 7/341) 0.003
Details of 30-day nonprocedure-related major complications including deaths
Heart failure 0% (n = 0/164) 0% (n = 0/341) Sepsis with or without multiorgan failure 6.1% (10/164) 0.9% (n = 3/341) 0.001
Respiratory arrest 0.6% (n = 1/164) ‡ 0% (n = 0/341) 0.325
Multiorgan failure without evidence of sepsis 0% (n = 0/164) 0% (n = 0/341) Stroke 0% (n = 0/164) 0% (n = 0/341) Arrhythmia 0% (n = 0/164) 0.9% (n = 3/341) 0.554 30-day nonprocedure-related deaths 6.7% (n = 11/164) 1.8% (n = 6/341) 0.007
Myocardial infarction 0% (n = 0/164) 0% (n = 0/341)
Abbreviations: CRP = C-reactive protein; IQR = interquartile range; SD = standard deviation; SVC = superior vena cava; TLE = transvenous lead extraction; TEE = transesophageal echocardiogram; TTE = transthoracic echocardiogram. † If more than one major complication (including death) occurred for a single TLE procedure, only one major complication or death was counted when calculating the "procedure-related major complication including procedure-related death" rate. ‡ The nonprocedure-related respiratory arrest in the local infection group was secondary to pneumonia.
TA B L E 6 Breakdown of causes of 30-day mortality for systemic and local infection subgroups
Systemic infection deaths Local infection deaths
Causes of 30-day mortality † (n = 13) (n = 7) Sepsis 84.6% (n = 11/13) 57.1% (n = 4/7) Arrhythmia 0 42.9% (n = 3/7) SVC tear 7.7% (n = 1/13) 0
End-stage heart failure 0 0 Pneumonia 7.7% (n = 1/13) 0
Abbreviations: SVC = superior vena cava. † 30-day procedure-and nonprocedure-related causes of deaths in patients with an infective indication for transvenous lead extraction.
30-day mortality
There was no statistically significant difference between the infective and noninfective groups in terms of procedure-related major complications including procedure-related deaths. The same was also true for the systemic and local infection subgroups. Low event numbers despite a large patient cohort may explain the lack of significant difference for these outcomes. However, the 30-day nonprocedure-related death rate was significantly higher in the infective indication group compared to the noninfective group (3.4% vs 0.2%, P < 0.001) and driven by nonprocedure-related sepsis. In the infective group, the majority of nonprocedure-related deaths were secondary to nonprocedurerelated sepsis (n = 13). The single nonprocedure-related death in the noninfective group was due to end-stage heart failure and not related to the extraction procedure. The 30-day nonprocedure-related death rate was significantly greater in the systemic infection group compared to the local infection group (6.7%, n = 11 vs 1.8%, n = 6, P = 0.007) and dominated by nonprocedure-related sepsis. In the systemic infection subgroup, nearly all of the nonprocedure-related deaths were due to nonprocedure-related sepsis (n = 10) and one was due to a respiratory arrest secondary to pneumonia. Therefore, patients with systemic infection indications for TLE appear to be a distinct high-risk group compared to patients with a localized infection/generator erosion indication for TLE. This has implications on consenting patients for TLE and higher risks should potentially be conveyed to patients with a systemic infection indication for TLE.
Whether this is directly related to prior valve surgery remains unclear and a dedicated study to investigate this is warranted.
Predictors of 30-day all-cause mortality
In the infective cohort, age, renal impairment, prior valve surgery, elevated pre-TLE CRP, and systemic infection were associated with 30-day all-cause mortality at univariate analysis ( Figure 1A ). Avoiding multicollinearity by not combing systemic infection with pre-TLE CRP in the same multivariate model, we identified renal impairment and systemic infection as independent predictors of 30-day all-cause mortality ( Figure 1B ) in the infective cohort. Elevated pre-TLE CRP was also an independent predictor of 30-day all-cause mortality along with renal impairment in a multivariate model which also included age and prior valve surgery as covariates ( Figure 1C ). Raised pre-TLE CRP is a well-recognized, albeit nonspecific, acute phase protein marker for systemic infection. We have previously shown that pre-TLE CRP is an independent predictor of 30-day mortality in an unselected cohort (infective and noninfective indications for TLE) with a CRP >72 mg/L as a suitable cut-off value from a receiver operator curve analysis for the prediction of 30-day mortality (sensitivity of 80%, specificity 90%, area under the curve 0.93, 95% confidence interval, 0.86-0.97). 8 In the systemic infection indication subgroup, renal impairment and pre-TLE CRP were associated with all-cause 30-day F I G U R E 1 Univariate logistic regression (A) and multivariate logistic regression (B, C) to predict 30-day mortality for patients with an infective indication (n = 505) for transvenous lead extraction. Abbreviations: CI = confidence interval; CRP = C-reactive protein; CRT = cardiac resynchronization therapy; DM = diabetes mellitus; HTN = hypertension; ICD = implantable cardioverter-defibrillator; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction; OR = odds ratio; TLE = transvenous lead extraction. Renal impairment was defined as estimated glomerular filtration rate < 60 mL/min/1.73 m 2 mortality at the univariate level. In a multivariate model including renal impairment, elevated pre-TLE CRP, and two additional important clinical covariates (age and prior valve surgery), no independent predictors of 30-day mortality were identified in the systemic infection subgroup. This most likely reflects the fact that systemic infection itself is a strong independent predictor of 30-day all-cause mortality as we have identified in the infective cohort.
Comparison with previous similar studies
The close similarity in the need for laser sheath extraction between systemic infection and "noninfective" groups has previously been reported by Pecha et al., albeit in a smaller sample size of 184 patients (systemic infection n = 52 vs noninfection n = 132) and they included patients with local pocket infection in their "noninfective" group which F I G U R E 2 Univariate logistic regression to predict 30-day mortality for patients with a systemic infection indication (n = 164) for transvenous lead extraction. Abbreviations: CI = confidence interval; CRP = C-reactive protein; CRT = cardiac resynchronization therapy; HTN = hypertension; ICD = implantable cardioverter-defibrillator; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction; OR = odds ratio; TLE = transvenous lead extraction. Renal impairment was defined as eGFR <60 mL/min/1.73 m 2 differs to our study groups. 9 Pecha et al. also found that the mean lead dwell time was similar between their systemic infection and "noninfected" groups 9 as in the current study. Pecha et al. also found no significant difference between their systemic infection and "noninfection" groups with regards to major complication in keeping with our study. 9 Deckx et al. investigated predictors of 30-day mortality in a retrospective cohort of 176 patients undergoing TLE for both infective and noninfective indications between January 2005 and December 2011 and found that only systemic infection was predictive of 30-day mortality. 10 In this present study, we have also shown that within an infective cohort undergoing TLE, systemic infection is an independent predictor of 30-day all-cause mortality at both the univariate and multivariate level.
LIMITATIONS
The findings in our study are subject to the inherent limitations with observational studies. There is the possibility of unknown confounders and bias between the operator management strategy and technique employed given no standardized protocol for TLE. Furthermore, TLE techniques and equipment have been modified over the study period which are not taken into account in the analysis. Patients referred directly for open surgical lead extraction were excluded from the database as the focus of this study was on TLE. The study is therefore not entirely representative of all patients requiring lead and system extractions. Predictors of 30-day mortality for the infective group and systemic infection subgroup were identified and discussed; however, the exact cause and effect relationship remains speculative. Despite a cohort of greater than 500 patients in the infective group and more than 150 patients in the systemic infection subgroup, our multivariate analyses were limited by the relatively low incidence of events in extracting potential risk factors of all-cause 30-day mortality. The study was not designed to compare the effect of different techniques, equipment, and approaches on 30-day mortality and additional data are warranted to explore this further. Furthermore, identifying additional variables such as duration of antibiotic therapy and time since diagnosis of CIED infection would have allowed further analysis with regards to identifying an optimal time to perform TLE; however, this information was not available in our prospectively collected database.
CONCLUSION
TLE in patients with an infective indication was associated with increased all-cause major complication including deaths, all-cause 30-day mortality, and nonprocedure-related mortality compared to noninfective patients. Sepsis was the main cause of 30-day mortality.
Renal impairment, systemic infection, and elevated preprocedure CRP were independent predictors of 30-day all-cause mortality in patients undergoing TLE for an infective indication.
TLE in patients with systemic infection was associated with increased all-cause major complication including deaths, all-cause 30-day mortality, and nonprocedure-related mortality compared to patients with local infection. Sepsis was the main cause of 30-day mortality. Renal impairment and elevated preprocedure CRP were associated with all-cause 30-day mortality at univariate analysis in patients undergoing TLE for a systemic infection indication. No independent predictors of 30-day mortality were identified in the systemic infection subgroup, which most likely reflects the fact that systemic infection itself is a strong independent predictor of 30-day all-cause mortality as identified in the infective cohort.
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